Cargando…

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subpopulations in acute myeloid leukemia (AML). PD-1 e...

Descripción completa

Detalles Bibliográficos
Autores principales: Guinn, Barbara-ann, Schuler, Patrick J., Schrezenmeier, Hubert, Hofmann, Susanne, Weiss, Johanna, Bulach, Christiane, Götz, Marlies, Greiner, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253334/
https://www.ncbi.nlm.nih.gov/pubmed/37298237
http://dx.doi.org/10.3390/ijms24119285
_version_ 1785056381137584128
author Guinn, Barbara-ann
Schuler, Patrick J.
Schrezenmeier, Hubert
Hofmann, Susanne
Weiss, Johanna
Bulach, Christiane
Götz, Marlies
Greiner, Jochen
author_facet Guinn, Barbara-ann
Schuler, Patrick J.
Schrezenmeier, Hubert
Hofmann, Susanne
Weiss, Johanna
Bulach, Christiane
Götz, Marlies
Greiner, Jochen
author_sort Guinn, Barbara-ann
collection PubMed
description Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subpopulations in acute myeloid leukemia (AML). PD-1 expression has been shown to increase with AML progression following allo-haematopoeitic stem cell transplantation, and therapy with hypomethylating agents. We have previously shown that anti-PD-1 can enhance the response of leukemia-associated antigen (LAA)-specific T cells against AML cells as well as leukemic stem and leukemic progenitor cells (LSC/LPCs) ex vivo. In concurrence, blocking of PD-1 with antibodies such as nivolumab has been shown to enhance response rates post-chemotherapy and stem cell transplant. The immune modulating drug lenalidomide has been shown to promote anti-tumour immunity including anti-inflammatory, anti-proliferative, pro-apoptotic and anti-angiogenicity. The effects of lenalidomide are distinct from chemotherapy, hypomethylating agents or kinase inhibitors, making lenalidomide an attractive agent for use in AML and in combination with existing active agents. To determine whether anti-PD-1 (nivolumab) and lenalidomide alone or in combination could enhance LAA-specific T cell immune responses, we used colony-forming immune and ELISpot assays. Combinations of immunotherapeutic approaches are believed to increase antigen-specific immune responses against leukemic cells including LPC/LSCs. In this study we used a combination of LAA-peptides with the immune checkpoint inhibitor anti-PD-1 and lenalidomide to enhance the killing of LSC/LPCs ex vivo. Our data offer a novel insight into how we could improve AML patient responses to treatment in future clinical studies.
format Online
Article
Text
id pubmed-10253334
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102533342023-06-10 A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells Guinn, Barbara-ann Schuler, Patrick J. Schrezenmeier, Hubert Hofmann, Susanne Weiss, Johanna Bulach, Christiane Götz, Marlies Greiner, Jochen Int J Mol Sci Article Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subpopulations in acute myeloid leukemia (AML). PD-1 expression has been shown to increase with AML progression following allo-haematopoeitic stem cell transplantation, and therapy with hypomethylating agents. We have previously shown that anti-PD-1 can enhance the response of leukemia-associated antigen (LAA)-specific T cells against AML cells as well as leukemic stem and leukemic progenitor cells (LSC/LPCs) ex vivo. In concurrence, blocking of PD-1 with antibodies such as nivolumab has been shown to enhance response rates post-chemotherapy and stem cell transplant. The immune modulating drug lenalidomide has been shown to promote anti-tumour immunity including anti-inflammatory, anti-proliferative, pro-apoptotic and anti-angiogenicity. The effects of lenalidomide are distinct from chemotherapy, hypomethylating agents or kinase inhibitors, making lenalidomide an attractive agent for use in AML and in combination with existing active agents. To determine whether anti-PD-1 (nivolumab) and lenalidomide alone or in combination could enhance LAA-specific T cell immune responses, we used colony-forming immune and ELISpot assays. Combinations of immunotherapeutic approaches are believed to increase antigen-specific immune responses against leukemic cells including LPC/LSCs. In this study we used a combination of LAA-peptides with the immune checkpoint inhibitor anti-PD-1 and lenalidomide to enhance the killing of LSC/LPCs ex vivo. Our data offer a novel insight into how we could improve AML patient responses to treatment in future clinical studies. MDPI 2023-05-26 /pmc/articles/PMC10253334/ /pubmed/37298237 http://dx.doi.org/10.3390/ijms24119285 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guinn, Barbara-ann
Schuler, Patrick J.
Schrezenmeier, Hubert
Hofmann, Susanne
Weiss, Johanna
Bulach, Christiane
Götz, Marlies
Greiner, Jochen
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title_full A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title_fullStr A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title_full_unstemmed A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title_short A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
title_sort combination of the immunotherapeutic drug anti-programmed death 1 with lenalidomide enhances specific t cell immune responses against acute myeloid leukemia cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253334/
https://www.ncbi.nlm.nih.gov/pubmed/37298237
http://dx.doi.org/10.3390/ijms24119285
work_keys_str_mv AT guinnbarbaraann acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT schulerpatrickj acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT schrezenmeierhubert acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT hofmannsusanne acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT weissjohanna acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT bulachchristiane acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT gotzmarlies acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT greinerjochen acombinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT guinnbarbaraann combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT schulerpatrickj combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT schrezenmeierhubert combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT hofmannsusanne combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT weissjohanna combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT bulachchristiane combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT gotzmarlies combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells
AT greinerjochen combinationoftheimmunotherapeuticdrugantiprogrammeddeath1withlenalidomideenhancesspecifictcellimmuneresponsesagainstacutemyeloidleukemiacells